Actively Recruiting
Can Astaxanthin Help Manage Asthma in POlluted Areas?
Led by Middlesex University · Updated on 2026-04-02
25
Participants Needed
1
Research Sites
9 weeks
Total Duration
On this page
Sponsors
M
Middlesex University
Lead Sponsor
A
AstaReal
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study will test whether astaxanthin, a naturally occurring antioxidant supplement, can improve lung function, reduce airway inflammation, and improve asthma control in adults with mild-to-moderate asthma. Participants will receive astaxanthin and placebo in random order in a double-blind crossover design. Each treatment period lasts 4 weeks and is separated by a 3-week washout period. The study also measures indoor and personal air pollution exposure to examine whether pollution influences asthma symptoms, airway responsiveness, and response to treatment. Exploratory thoracic bioelectrical impedance spectroscopy will be assessed alongside standard respiratory tests.
CONDITIONS
Official Title
Can Astaxanthin Help Manage Asthma in POlluted Areas?
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years or older
- Confirmed clinical diagnosis of mild-to-moderate asthma consistent with BTS/NICE/SIGN (2024)
- Asthma managed at GINA (2024) step 1-3 therapy with stable maintenance treatment for at least 4 weeks prior to enrollment
- No asthma exacerbation requiring systemic corticosteroids within the past 6-8 weeks
- Ability to perform acceptable and repeatable spirometry according to ATS/ERS standards
- Willing to avoid antioxidant and anti-inflammatory supplements during the study
- Not consuming high dietary sources of astaxanthin such as frequent salmonid or crustacean intake
- Non-smoking and non-vaping
- Able and willing to take daily study capsules and attend all required visits
- Able and willing to complete home monitoring including peak flow, air-quality monitoring, and questionnaires
- Able to provide written informed consent
You will not qualify if you...
- Current smokers or vapers
- Respiratory tract infection within the past 4 weeks
- Pregnant or lactating individuals
- Significant co-morbidities including cardiovascular disease, autoimmune, or systemic inflammatory diseases
- Renal or gastrointestinal disorders affecting astaxanthin absorption or metabolism
- Known allergy or hypersensitivity to astaxanthin or study supplement components
- History or current evidence of alcohol or substance abuse
- Participation in another interventional drug or supplement study within the past 3 months
- Use of medicines with a narrow therapeutic index posing risk of supplement interactions (e.g., ciclosporin, tacrolimus, warfarin)
- Other significant chronic respiratory diseases such as COPD or bronchiectasis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Middlesex University
London, Barnet, United Kingdom, NW4 4BT
Actively Recruiting
Research Team
A
Ahmet Celen, PhD in Biomedical Science
CONTACT
D
Dr Lygeri Dimitriou
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here